Edition:
United Kingdom

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

2.59USD
19 Oct 2018
Change (% chg)

$-0.07 (-2.63%)
Prev Close
$2.66
Open
$2.68
Day's High
$2.70
Day's Low
$2.57
Volume
27,350
Avg. Vol
139,578
52-wk High
$16.85
52-wk Low
$1.98

Latest Key Developments (Source: Significant Developments)

Aquinox Pharmaceuticals Received Notice Terminating License Agreement That Had Been Entered Between Co's Unit And Astellas US LLC
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Astellas Pharma Inc <4503.T>::AQUINOX PHARMACEUTICALS - ON SEPT 4, RECEIVED NOTICE TERMINATING LICENSE AGREEMENT THAT HAD BEEN ENTERED BETWEEN CO'S UNIT AND ASTELLAS US LLC.AQUINOX PHARMACEUTICALS INC - TERMINATION OF THE ASTELLAS AGREEMENT WILL BE EFFECTIVE MARCH 4, 2019- SEC FILING.  Full Article

Aquinox Pharmaceuticals Q2 Earnings Per Common Stock $0.12
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.AQUINOX PHARMACEUTICALS INC QTRLY EARNINGS PER COMMON STOCK $0.12.AQUINOX PHARMACEUTICALS INC QTRLY REVENUE $25 MILLION.  Full Article

Ecor1 Capital Reports 7.5 Pct Passive Stake In Aquinox Pharmaceuticals
Monday, 16 Jul 2018 

July 16 (Reuters) - Aquinox Pharmaceuticals Inc ::ECOR1 CAPITAL, LLC REPORTS A 7.5 PERCENT PASSIVE STAKE IN AQUINOX PHARMACEUTICALS AS OF JULY 5, 2018- SEC FILING.  Full Article

Aquinox Pharmaceuticals Says Approved Restructuring Plan Under Which Co Reduced Its Workforce By 30 Employees
Monday, 9 Jul 2018 

July 9 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS - ON JULY 3, APPROVED RESTRUCTURING PLAN UNDER WHICH CO REDUCED ITS WORKFORCE BY 30 EMPLOYEES AND CLOSED ITS OFFICE IN SAN BRUNO.AQUINOX PHARMACEUTICALS SAYS REGARDING RESTRUCTURING, CO ESTIMATES THAT IT WILL INCUR TOTAL RESTRUCTURING CHARGES OF ABOUT $2.5 MILLION - SEC FILING.AQUINOX PHARMA - ON JULY 3, APPROVED RESTRUCTURING PLAN AFTER JUNE 27 ANNOUNCEMENT THAT PHASE 3 LEADERSHIP 301 CLINICAL TRIAL FAILED TO MEET PRIMARY ENDPOINT.  Full Article

Aquinox Pharmaceuticals qtrly ‍net loss per share $0.50​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aquinox Pharmaceuticals Inc -:Aquinox Pharmaceuticals announces third quarter 2017 financial results.Aquinox Pharma - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and at least to mid-2019.Aquinox Pharmaceuticals Inc - qtrly ‍net loss per common stock $0.50​.Aquinox Pharmaceuticals - ‍cash, cash equivalents, short-term, long-term investments totaled $119.7 million as of Sept 30 versus 153.1 million as of Dec 31, 2016​.  Full Article

UPDATE 2-Aquinox to stop development of lead drug; shares plunge

June 27 Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent.